prof. dr. A.D.R. (Alwin) Huitema

prof. dr. A.D.R. (Alwin) Huitema

Full Professor
prof. dr. A.D.R. (Alwin) Huitema
  • Clinical Pharmacy

Research Programs


Side Activities

2002 - 2021 : Member of the Medical Ethical Committee of Netherlands Cancer Institute

2003 - : Involved in many early clinical trials of novel anticancer agents (not further specified, revenues for Netherlands Cancer Institute, Princess Máxima Center or University Medical Center Utrecht)

2016 - 2018: Member of scientific councel "Stichting Kinderen Kankervrij (KiKa)"

2017 - 2021 : Member of the working group Oncology & Hematology of "Horizonscan geneesmiddelen", ZorgInstituut Nederland

2018 - 2023: Board member of Dutch Society of Clinical Pharmacology & Biopharmaceutics

2021 - 2022: Member of the external evaluation committee of 10 year program "Goed Geneesmiddelen Gebruik"

2023 - : Member of the working party for the "Kennisagenda 2.0" of the Dutch Association of Hospital Pharmacists

2023 -: Member of the "Concilium" of the Dutch Association of Hospital Pharmacists

Fellowship and Awards

2015 Galenus research prize

2014 Huizinga penning of the Dutch Association of Hospital Pharmacists

Research Output (286)

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

Damoiseaux D, van Hasselt J G C, Amant F C H, van Calsteren K, Beijnen J H, Huitema A D R, Dorlo T P C Aug 2023, In: Clinical Pharmacokinetics. 62 , p. 1157-1167 11 p.

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

van Eerden Ruben A G, IJzerman Nikki S, van Meekeren Milan, Oomen-de Hoop Esther, Guchelaar Niels A D, Visser Andrea M W, Matic Maja, van Schaik Ron H N, de Bruijn Peter, Moes Dirk-Jan A R, Jobse Pieter A, Gelderblom Hans, Huitema Alwin D R, Steeghs Neeltje, Mathijssen Ron H J, Koolen Stijn L W, Aug 2023, In: Clinical Pharmacokinetics. 62 , p. 1129-1139 11 p.

Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients

Lanser Daan A C, Van der Kleij Maud B A, Veerman G D Marijn, Steeghs Neeltje, Huitema Alwin D R, Mathijssen Ron H J, Oomen-de Hoop Esther Jul 2023, In: Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 163 6 p.

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach

Damoiseaux David, Centanni Daniel, Beijnen Jos H, Amant Frédéric, Huitema Alwin D R, Dorlo Thomas P C Jul 2023, In: Clinical Pharmacokinetics. 62 , p. 969-980 12 p.

Predicting the effect of different folate doses on [ 68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling.

Siebinga Hinke, Hendrikx Jeroen J M A, Huitema Alwin D R, de Wit-van der Veen Berlinda J 15 Jun 2023, In: EJNMMI Research. 13 , p. 1-9

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

Van Der Heijden Lisa T., Nijstad A. Laura, Uittenboogaard Aniek, Beijnen Jos H., Dorlo Thomas P.C., Kaspers Gertjan J.L., Huitema Alwin D.R. 1 Jun 2023, In: Therapeutic drug monitoring. 45 , p. 354-363 10 p.

Ion suppression, reduced long-term robustness and leakage current of the spray voltage during the ionization of trichloroacetic acid; a case study with a methylmalonic acid assay

Punt Arjen M., van der Elst Kim C.M., Huitema Alwin D.R., Lentjes Eef G.W.M. 30 May 2023, In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 1224

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer:A biomarker-enriched phase II study

Embaby Alaa, Kutzera Joachim, Geenen Jill J, Pluim Dick, Hofland Ingrid, Sanders Joyce, Lopez-Yurda Marta, Beijnen Jos H, Huitema Alwin D R, Witteveen Petronella O, Steeghs Neeltje, van Haaften Gijs, van Vugt Marcel A T M, de Ridder Jeroen, Opdam Frans L 24 May 2023, In: Gynecologic Oncology. 174 , p. 239-246 8 p.

Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry:A Method Validation Study and Future Perspectives

Smeijsters Erin H, van der Elst Kim C M, Visch Amy, Göbel Camiel, Loeff Floris C, Rispens Theo, Huitema Alwin D R, van Luin Matthijs, El Amrani Mohsin 12 May 2023, In: Pharmaceutics. 15

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

Veerman G D Marijn, Boosman Rene J, Jebbink Merel, Oomen-de Hoop Esther, van der Wekken Anthonie J, Bahce Idris, Hendriks Lizza E L, Croes Sander, Steendam Christi M J, de Jonge Evert, Koolen Stijn L W, Steeghs Neeltje, van Schaik Ron H N, Smit Egbert F, Dingemans Anne-Marie C, Huitema Alwin D R, Mathijssen Ron H J May 2023, In: EClinicalMedicine. 59 11 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not